Drug or intervention
Aripiprazole Clinical Trials
Studies that test Aripiprazole, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 17Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
The goal of this clinical trial is to test whether a personalized approach to treatment selection improves symptoms in older adults with treatment-resistant depression.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- BAARD (NCT07810738)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation
- Where
- 3 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
Stuttering, Adult
Dopamine and Sensorimotor Function in Stuttering
This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency.
- Trial name
- NCT07215884
- Testing
- Aripiprazole 10 MG
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophenia Disorder
Biomarkers to Enhance Early Schizophrenia Treatment
This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
- Trial name
- BEEST (NCT06969755)
- Testing
- aripiprazole, risperidone, clozapine
- Where
- 5 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Northwell Health
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog")…
- Trial name
- PAISE-AriSE (NCT07714213)
- Testing
- Aripiprazole (low-dose, 1mg)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Christiana Franke
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Schizophrenia
Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.
The primary objective of this study is to evaluate the bioequivalence of aripiprazole for injection (Test product, 400 mg) compared with Abilify Maintena® (Reference product, 400 mg) at steady state in patients with…
- Trial name
- NCT07547384
- Testing
- Aripiprazole for Injection
- Volunteers
- 116 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Depression, Sequestra
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
This project aims to investigate the effectiveness of existing common antidepressants and to provide new evidence for depressed children and adolescents who are not responding to their first treatment.
- Trial name
- STAR-AD (NCT05814640)
- Testing
- Fluoxetine, Sertraline, Vortioxetine
- Where
- China
- Volunteers
- 520 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Completed, with results posted
All –Chronic Low Back Pain, Negative Affectivity
Treating Negative Affect in Low Back Pain Patients
This study will examine how the use of antidepressant, physical therapy, and combination of both affects pain, function, and depression outcomes in chronic low back pain patients.
- Trial name
- TNA-LBP (NCT04747314)
- Testing
- Antidepressant, Enhanced Fear Avoidance Rehabilitation
- Where
- 3 sites in United States
- Volunteers
- 308 people
- Sponsor
- Ajay Wasan, MD, Msc
Autistic Disorder, Behavioral Symptoms
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 [NCT00332241]…
- Trial name
- NCT00365859
- Testing
- Aripiprazole
- Where
- 55 sites in United States
- Volunteers
- 330 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Mania
Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents
The purpose of this trial is to assess the safety, tolerability and pharmacokinetics of aripiprazole tablets following oral administration to children and adolescents.
- Trial name
- NCT00102479
- Testing
- Aripiprazole
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the this trial is to evaluate the efficacy, safety, and tolerability of an intramuscular (IM) depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia The trial is designed into…
- Trial name
- ASPIRE (NCT00706654)
- Testing
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg
- Where
- 98 sites in United States, Austria and 13 more
- Volunteers
- 937 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.